Use of Biperiden for the Prevention of Post-traumatic Epilepsy
Summary
There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.
Timeline
- Start
- 2018-01-31
- Primary completion
- 2022-12-02
- Completion
- 2022-12-02
Outcome
Missed primary endpoint
Stopped (Enrollment): “Recruitment and funding issues, together with the event of the SARS-CoV-2 pandemic prompted an adjustment in the study design to stop enrollment at 123 patients.”
paper Data analysis indicated lack of evidence of biperiden for either, the incidence of post-traumatic epilepsy (2.6, 95%CI, 0.65-10.57; p = 0.170) PMID 39175759 ↗
Publications
- Romariz SAA, Marinelli BPT, Bergo MFC, Foresti ML, Mello LE. Evaluation of long-term quality of life in traumatic brain injury patients early treated with biperiden - a randomized controlled trial. BMC Neurol. 2026 Jun 1;26(1):411. doi: 10.1186/s12883-026-05029-7.
- Foresti ML, Garzon E, de Moraes MT, Valeriano RPS, Santiago JP, Dos Santos GM, Longo NM, Baise C, Andrade JCQF, Susemihl MA, Leite CDC, Naffah Mazzacoratti MDG, Paiva WS, de Andrade AF, Teixeira MJ, Mello LE. Initial clinical evidence on biperiden as antiepileptogenic after traumatic brain injury-a randomized clinical trial. Front Neurol. 2024 Aug 7;15:1443982. doi: 10.3389/fneur.2024.1443982. eCollection 2024.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Biperiden | Small molecule | 5 mg | Intravenous |